Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-Current Debt (2024 - 2025)

Editas Medicine (EDIT) has disclosed Non-Current Debt for 2 consecutive years, with $54.1 million as the latest value for Q3 2025.

  • Quarterly Non-Current Debt changed N/A to $54.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $54.1 million through Sep 2025, changed N/A year-over-year, with the annual reading at $52.4 million for FY2024, N/A changed from the prior year.
  • Non-Current Debt for Q3 2025 was $54.1 million at Editas Medicine, up from $51.7 million in the prior quarter.
  • The five-year high for Non-Current Debt was $54.1 million in Q3 2025, with the low at $49.6 million in Q1 2025.